Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Cost of Revenue (2023 - 2025)

Immunocore Holdings' Cost of Revenue history spans 3 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 719.09% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $5.1 million, up 86.27%, while the annual FY2025 figure was $5.1 million, 86.27% up from the prior year.
  • Cost of Revenue for Q4 2025 was $2.7 million at Immunocore Holdings, up from $513000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $2.7 million in Q4 2025 and bottomed at $200000.0 in Q4 2023.
  • The 3-year median for Cost of Revenue is $397000.0 (2023), against an average of $737916.7.
  • The largest YoY upside for Cost of Revenue was 719.09% in 2025 against a maximum downside of 39.07% in 2025.
  • A 3-year view of Cost of Revenue shows it stood at $200000.0 in 2023, then surged by 65.0% to $330000.0 in 2024, then surged by 719.09% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Cost of Revenue are $2.7 million (Q4 2025), $513000.0 (Q3 2025), and $1.0 million (Q2 2025).